{"id":197282,"date":"2026-11-03T10:11:12","date_gmt":"2026-11-03T10:11:12","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/197282\/"},"modified":"2026-11-03T10:11:12","modified_gmt":"2026-11-03T10:11:12","slug":"lilly-stock-near-a-high-what-can-democrats-change","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/197282\/","title":{"rendered":"Lilly Stock Near A High: What Can Democrats Change?"},"content":{"rendered":"<p>For questions about this article or underlying research, email help@trefis.com.<\/p>\n<p class=\"start\">Part of our midterms guide. <a href=\"https:\/\/www.trefis.com\/articles\/621985\/will-the-midterms-move-your-stocks\/2026-11-02?from=LLY_bigstory_mid49_2026-11-03&amp;mod=art_top_startherewhatthevotereal\" rel=\"nofollow noopener\" target=\"_blank\">Start here: what the vote really changes for your money<\/a>.<\/p>\n<p>Betting markets give Democrats about a 94% chance of winning the House on Tuesday, and about three in four of taking the Senate too. President Trump keeps his veto. For drug stocks, the twist is that the toughest pricing moves of the past year came from a Republican White House. The question is what\u2019s left for Congress to do.<\/p>\n<p>Company<br \/>\nValue<br \/>\n12-month return<br \/>\nWhat\u2019s at stake<br \/>\nExposure to the vote<\/p>\n<p>Eli Lilly (LLY)<br \/>\n$1.26T<br \/>\n+65%<br \/>\nMedicare coverage of obesity drugs<br \/>\nMedium<\/p>\n<p>Merck (MRK)<br \/>\n$366B<br \/>\n+78%<br \/>\nMedicare negotiation of cancer drugs<br \/>\nMedium<\/p>\n<p>Novo Nordisk (NVO)<br \/>\n$180B<br \/>\n\u221214%<br \/>\nSame as Lilly, with a weaker hand<br \/>\nMedium<\/p>\n<p>Pfizer (PFE)<br \/>\n$175B<br \/>\n+33%<br \/>\nFirst to sign a price deal; tariff relief to 2029<br \/>\nLow<\/p>\n<p>The scariest policy for drugmakers is already priced in. The stocks went up anyway.<\/p>\n<p>Pfizer closed at a 52-week high, and <a href=\"https:\/\/www.trefis.com\/data\/companies\/LLY?from=LLY_bigstory_mid49_2026-11-03&amp;mod=co_top_lilly\" rel=\"nofollow noopener\" target=\"_blank\">Lilly<\/a> within 1% of one. Lilly\u2019s sales rose 39% last quarter, to $24.4 billion, on its obesity and diabetes drugs. Products, not politics, drove the year.<\/p>\n<p>See more lines: how we ranked them<\/p>\n<p>Exposure is our judgment of how much Tuesday\u2019s outcome can change each company\u2019s revenue, costs or legal risk, given that a Democratic House can investigate, write budgets and block bills, but can\u2019t pass laws past a veto. Values and returns are at the Nov 2 close (Trefis market data). Novo Nordisk\u2019s U.S.-listed shares are down about 17% in 2026. For scale: Johnson &amp; Johnson ($652B, +46%) and AbbVie ($511B, +36%).<\/p>\n<p><img decoding=\"async\" style=\"display: block; width: 100%; max-width: 640px; height: auto;\" src=\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/11\/pills-5693575_1920.jpg\" width=\"640\"\/>Image from Pixabay<br \/>\nWhat Has The White House Already Done?<\/p>\n<p>Three things. First, price deals. Pfizer signed first, in 2025, and the White House says 26 drugmakers now cover 89% of the branded market. They cut prices for Medicaid and cash buyers and promise the lowest rich-country price on new drugs.<\/p>\n<p>Second, tariffs. Signers are exempt from a 100% tariff on patented drugs through January 2029. That\u2019s past the next presidential election, and no House vote changes it.<\/p>\n<p>Third, obesity drugs. Under the Lilly and Novo deals, Medicare pays $245 a month for Wegovy and Zepbound, and patients pay $50. A pilot started July 1 for patients with severe obesity, or obesity plus a related illness.<\/p>\n<p>And Medicare Negotiation?<\/p>\n<p>It runs on its own. The 2022 law that set it up was a Democratic law, and it still stands. For the first time, the 2028 round includes drugs given in doctors\u2019 offices, like Botox. Medicare must publish those prices by Nov. 30, 2026, four weeks after the vote. Keytruda, Merck\u2019s biggest seller, isn\u2019t on that list, but Lilly\u2019s Trulicity is.<\/p>\n<p>So What Can A Democratic House Change?<\/p>\n<p>Hearings on the deals. Most terms are private. Democrats will ask whether the cuts are real. One report found the price site listed fewer than 12% of the signers\u2019 brand drugs in July.<\/p>\n<p>The obesity pilot. It\u2019s a pilot, not a law. It ends in December 2027, and a lasting benefit needs Congress. That\u2019s Lilly\u2019s and Novo\u2019s biggest political upside, not risk.<\/p>\n<p>The 2027 debt limit. Democrats want health-care money back. More drugs in Medicare negotiation, sooner, is a classic way to pay for it. That\u2019s the one real threat, and it\u2019s a 2027 story.<\/p>\n<p>What Could Go Wrong?<\/p>\n<p>Both parties like cutting drug prices. A populist White House and a Democratic House could agree to write the deals into law, which would make them permanent. And the obesity race could turn: Lilly is priced for leadership, and Novo shows how fast a leader can slip.<\/p>\n<p>Most exposed: Merck and Novo Nordisk. Least: Pfizer. The price deals, the tariff relief and Medicare negotiation were decided before Tuesday. Watch Nov. 30 for the 2028 Medicare prices and the 2027 debt limit for new cuts. Lilly may even gain if Congress makes obesity coverage permanent.<\/p>\n<p>For the big picture, see <a href=\"https:\/\/www.trefis.com\/articles\/621985\/will-the-midterms-move-your-stocks\/2026-11-02?from=LLY_bigstory_mid49_2026-11-03&amp;mod=art_end_willthemidtermsmoveyours\" rel=\"nofollow noopener\" target=\"_blank\">Will The Midterms Move Your Stocks?<\/a> Health care\u2019s likely winners: <a href=\"https:\/\/www.trefis.com\/articles\/621984\/3-stocks-that-could-pop-if-democrats-win\/2026-11-02?from=LLY_bigstory_mid49_2026-11-03&amp;mod=art_end_3stocksthatcouldpopifdem\" rel=\"nofollow noopener\" target=\"_blank\">3 stocks that could pop if Democrats win<\/a>.<\/p>\n<p>How Much Of Your Portfolio Rides On One Drug?<\/p>\n<p>Elections change the odds, not your plan. If you have $1 million or more invested, <a href=\"https:\/\/www.trefis.com\/wealth-management?abTest=a&amp;from=wmL2_MIDDRUG-2026-11&amp;mod=hq_end_seewhattuesdaymeansforyo\" rel=\"nofollow noopener\" target=\"_blank\">see what Tuesday means for your portfolio<\/a> in a free 15-minute call with a Trefis partner firm.<\/p>\n<p>Spot an error or want more like this? <a href=\"https:\/\/www.trefis.com\/data\/v2\/rankings\/article-feedback?r=LLY_20261103_mid49&amp;t=LLY\" rel=\"nofollow noopener\" target=\"_blank\">Tell us in 10 seconds<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"For questions about this article or underlying research, email help@trefis.com. Part of our midterms guide. Start here: what&hellip;\n","protected":false},"author":2,"featured_media":197283,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[61122,88309,88312,64737,3860,9416,88310,88311,15275,272,3859,15274],"class_list":["post-197282","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-abbv","tag-drug-stocks","tag-jnj","tag-lilly-stock","tag-lly","tag-lly-stock","tag-medicare-drug-prices","tag-midterm-elections-stocks","tag-mrk","tag-novo-nordisk","tag-nvo","tag-pfe"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117551975408545510","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/197282","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=197282"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/197282\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/197283"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=197282"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=197282"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=197282"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}